ViroGates Investor Relations

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; and suPARnostic Quick Triage kit for use in the point of care situation for early warning and patient triaging that allows clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression, and outcome. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.

Read Less